Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients ; volume:22 ; number:1 ; day:5 ; month:3 ; year:2022 ; pages:1-10 ; date:12.2022
BMC cancer ; 22, Heft 1 (5.3.2022), 1-10, 12.2022
- Creator
-
Horimoto, Yoshiya
Ishizuka, Yumiko
Ueki, Yuko
Higuchi, Toru
Arakawa, Atsushi
Saito, Mitsue
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09351-4
- URN
-
urn:nbn:de:101:1-2022060123384260948334
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Horimoto, Yoshiya
- Ishizuka, Yumiko
- Ueki, Yuko
- Higuchi, Toru
- Arakawa, Atsushi
- Saito, Mitsue
- SpringerLink (Online service)
Other Objects (12)
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer